Product Description
Mechanisms of Action: TR Inhibitor
Novel Mechanism: No
Modality: N/A
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: ERYtech Pharma
Company Location: LYON I0 69008
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Pancreatic Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| None | P1 |
None |
Pancreatic Cancer |
None |
None |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
10/09/2023 |
News Article |
Dermatology Device Market Growth Rate And Competition Landscape, Forecast From 2023 To 2032 |